Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Natasha Kekre; Haesook T. Kim; Julia Hofer; Vincent T. Ho; John Koreth; Philippe Armand; Sarah Nikiforow; Mahasweta Gooptu; Rizwan Romee; Edwin P. Alyea; Prashant Nageshwar; Brett Glotzbecker; Areej El-Jawahri; Zachariah DeFilipp; Robert J. Soiffer; Joseph H. Antin; Yi Bin Chen; Corey Cutler

ArticleOPEN ACCESS

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Bone Marrow Transplantation

DOI: 10.1038/s41409-020-01083-y

1Citations

8Readers

Get full text

Abstract

The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.

Cite

CITATION STYLE

APA

Kekre, N., Kim, H. T., Hofer, J., Ho, V. T., Koreth, J., Armand, P., … Cutler, C. (2021, May 1). Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0). Bone Marrow Transplantation. Springer Nature. https://doi.org/10.1038/s41409-020-01083-y

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Abstract

Cite

Register to see more suggestions